Ondran (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondran, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for oral use. It treats and helps prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adults and children.

GNH USA supplies Ondran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps prevent emesis during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of vomiting after surgical procedures. - Hyperemesis gravidarum (off‑label in some regions): may be used when conventional therapy fails, under specialist supervision.

Side‑effect profiles reflect the drug’s pharmacology and patient variability.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel motility. - Diarrhoea: occasional loose stools. - Fatigue: general feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant‑like reactions: very uncommon but serious.

Patients should be assessed for cardiac risk and drug interactions before starting therapy.

- Cardiac monitoring: evaluate baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Renal or hepatic impairment: dose adjustment may be required; follow prescriber guidance. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ondansetron may alter the pharmacokinetics of several medicines and vice‑versa.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): potential for altered metabolism. - Tramadol and other serotonergic analgesics: monitor for signs of serotonin syndrome. - Oral contraceptives: may slightly reduce efficacy; advise backup contraception.